Transforming drug development with a fully outsourced model: Lessons learned for biopharmaceuticals

American Pharmaceutical Outsourcing

Volumn 10, Issue 3, 2009, Pages 18-25

  Roberson, Terri A ^a   Smith, Neil V ^a   Scherer, Joel ^b  

^a Chorus Operations ^*

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449376993     PISSN: 15296318     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Tufts Center for the Study of Drug Development. 2008. Outlook 2008.
2. Longman, R. 2007. Lilly's Chorus experiment. IN VIVO: The Business & Medicine Report. 25(5):1-5.
3. Longman, R. 2007. Flexion-The in-licensing advantage of cheap proof-of-concept. Start-Up. 12(10):1-2.
4. PriceWaterhouseCoopers. 2007. Pharma 2020: The Vision - which path will you take? www.pwc.com/pharma. Accessed 12 January 2009.
5. Smith NV, Roberson TA. 2008. Transforming drug development. A fully outsourced model. Pharma Focus Asia. 9:39-41.
6. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: new estimates of drug development costs. J Health Econ. 22:151-85.
7. Adams CP, Brantner VV. 2006. Estimating The Cost Of New Drug Development: Is It Really $802 Million? Health Affairs 25(2): 420-428.